Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
BPDCN is ultimately a bone marrow disease requiring induction-type eradication therapy followed by hematopoietic stem cell transplant (HSCT) to achieve long-lasting remissions or cure. Various regimens have been applied to this disease with varying success. A cumulative review of the literature suggests more intense regimens have greater efficacy with acute lymphoblastic leukemia regimens preferred to acute myeloid leukemia regimens. This approach benefits fit patients who are eligible for HSCT; however, most BPDCN patients require other treatment options. The recent FDA approval of the CD123-targeted agent tagraxofusp provides a novel therapeutic alternative to traditional chemotherapy but with potential toxicities.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Michael Haddadin, Justin Taylor Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Toxicology | Transplants